Evidence map›Paper›PMID 33983522›Full record

ReviewCurrent atherosclerosis reports2021

COVID and Cardiovascular Disease: What We Know in 2021.

Michael Chilazi, Eamon Y Duffy, Aarti Thakkar, Erin D Michos

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current atherosclerosis reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 3 pooled it
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 3 syntheses or guidelines pooled it, 107 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Clinical patterns of somatic symptoms in patients suffering from post-acute long COVID: a systematic review.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022
    Pooled it
  4. Trial
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Observational
  13. Article
  14. Alterations of whole body glucose metabolism in a feline SARS-CoV-2 infection model.American journal of physiology. Regulatory, integrative and comparative physiology · 2024
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. [Severe coronavirus-2 infection background for cardiovascular complications].Revista medica del Instituto Mexicano del Seguro Social · 2024
    Observational
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Michael ChilaziDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Eamon Y DuffyDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Aarti ThakkarDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Erin D MichosDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. edonnell@jhmi.edu.ORCID http://orcid.org/0000-0002-5547-5084
Johns Hopkins University · US

Funding

Johns Hopkins University Amato Fund in Women's Cardiovascular Health
6 · The paper itself

Abstract

purpose of reviewCoronavirus disease 2019 (COVID-19) has been the cause of significant global morbidity and mortality. Here, we review the literature to date of the short-term and long-term consequences of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection on the heart. RECENT

findingsEarly case reports described a spectrum of cardiovascular manifestations of COVID-19, including myocarditis, stress cardiomyopathy, myocardial infarction, and arrhythmia. However, in most cases, myocardial injury in COVID-19 appears to be predominantly mediated by the severity of critical illness rather than direct injury to myocardium from viral particles. While cardiac magnetic resonance imaging remains a powerful tool for diagnosing acute myocarditis, it should be used judiciously in light of low baseline prevalence of myocarditis. Guiding an athletic patient through return to play (RTP) after COVID-19 infection is a challenging process. More recent data show RTP has been a safe endeavor using a screening protocol. "Long COVID" or post-acute sequelae of SARS-CoV-2 infection has also been described. The reported symptoms span a large breadth of cardiopulmonary and neurologic complaints including fatigue, palpitations, chest pain, breathlessness, brain fog, and dysautonomia including postural tachycardia syndrome (POTS). Management of POTS/dysautonomia primarily centers on education, exercise, and salt and fluid repletion. Our understanding of the impact of COVID-19 on the cardiovascular system is constantly evolving. As we enter a new age of survivorship, additional research is needed to catalogue the burden of persistent cardiopulmonary symptoms. Research is also needed to learn how acute management may alter the likelihood and prevalence of this chronic syndrome.

Indexed as

Return to SportSARS-CoV-2AthletesCardiovascular DiseasesCOVID-19HumansMagnetic Resonance ImagingPost-Acute COVID-19 SyndromePrognosisSeverity of Illness IndexTroponinTroponinCardiovascular diseaseCOVID-19Long COVIDReturn to playSARS-CoV2

Identifiers

PMID33983522
PMCPMC8117457
OpenAlexW3160020671

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.